Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million.
SKYE · Skye Bioscience, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Skye Bioscience, Inc. said a jury returned a unanimous verdict in its favor on all claims in the Wendy Cunning lawsuit on November 10, 2026. Judgment is expected in due course, but the plaintiff may file post-trial motions or appeal.
Skye Bioscience said a jury returned a unanimous verdict in its favor on all claims in former employee Wendy Cunning’s whistleblower and retaliation lawsuit on November 10, 2026. Judgment is expected soon, but post-trial motions or an appeal remain possible.
Skye Bioscience proposes acquiring Redx Pharma Limited, renaming the combined company Fibrx Therapeutics, Inc., and seeking stockholder approval for related share issuances, financing, charter amendments, compensation and meeting adjournment.